Research / Brain / Drugs / Drug / Health / Microbiology / Boston / Boston blog main / Boston top stories / National blog main / New York blog main / New York top stories / San Francisco blog main / San Francisco top stories / AbbVie / Autism / Axial Biotherapeutics / B. fragilis / California Institute of Technology / Columbia University / David Donabedian / deals / Domain Associates / GlaxoSmithKline / James Blair / Kallyope / Life Sciences / Longwood Fund / Michelle Dipp / Microbiome / Nancy Thornberry / Parkinson's Disease / Sarkis Mazmanian / seres Therapeutics / startups / VC

With $19M, Axial Becomes Latest Startup to Target Gut-Brain Connection

Posted on: Nov 30, 2016   |   Posted by: Biotech Mag

With $19M, Axial Becomes Latest Startup to Target Gut-Brain Connection

We're still a long way from understanding how the trillions of bacteria that live in and on our bodies, known collectively as the human microbiome, affect our health and...

Continue reading ...



Other Posts from Biotech Mag